Speech-Language Pathologists in Claymont, DE Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Karen Thomas Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3937

Susan Kushmeider, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3994

Roberta L Oneill Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3937

Patricia Bailey Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Maple Ln, Claymont, DE 19703 Phone: 302-792-3994

Joan Lochrie Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3994

Jenine Goren Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3937

Aline M Holler Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pennsylvania Ave, Claymont, DE 19703 Phone: 302-792-3937

Therese Taha Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Maple Ln, Claymont, DE 19703 Phone: 302-792-3994

News Archive

School-based program lowers obesity and risk factors for type 2 diabetes in high risk youth

An intervention in middle schools lowered the obesity rate in students at highest risk for type 2 diabetes, those who started out overweight or obese in sixth grade, an NIH-funded study has found. However, schools that implemented the program did not differ from comparison schools in the study's primary outcome-the prevalence of overweight and obesity combined-which had declined 4 percent in both groups of schools by the end of the three-year study.

Roche obtains global co-exclusive license for PI3K biomarker from QIAGEN

Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN's wholly owned subsidiary DxS, now QIAGEN Manchester.

Study shows link between changing rates of antibiotic consumption and resistance

A new study published in Clinical Infectious Diseases and available online shows how seasonal changes in outpatient antibiotic use - retail sales of antibiotics typically get a boost during the winter - can significantly alter seasonal patterns of drug resistance. The findings suggest that hospital campaigns to reduce inappropriate antibiotic use should be coordinated with efforts in the broader community if they are to be most effective.

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo. Targeting CTR2 was shown to decrease drug resistance to cisplatin.

Read more Medical News

› Verified 9 days ago